Blair William & Co. IL Decreases Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Blair William & Co. IL decreased its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 1.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 417,894 shares of the company's stock after selling 8,019 shares during the period. Blair William & Co. IL owned about 0.80% of PROCEPT BioRobotics worth $33,649,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its holdings in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after acquiring an additional 145 shares in the last quarter. Naviter Wealth LLC increased its position in shares of PROCEPT BioRobotics by 6.0% during the fourth quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock valued at $249,000 after acquiring an additional 176 shares in the last quarter. Amundi lifted its holdings in shares of PROCEPT BioRobotics by 0.9% during the fourth quarter. Amundi now owns 20,143 shares of the company's stock valued at $1,742,000 after purchasing an additional 183 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of PROCEPT BioRobotics by 1.5% during the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock valued at $1,150,000 after acquiring an additional 218 shares during the last quarter. Finally, KRS Capital Management LLC lifted its position in PROCEPT BioRobotics by 0.5% during the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock valued at $3,741,000 after purchasing an additional 225 shares during the period. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Trading Up 0.6 %

Shares of NASDAQ PRCT traded up $0.38 during trading hours on Tuesday, hitting $58.64. 186,190 shares of the company traded hands, compared to its average volume of 750,632. PROCEPT BioRobotics Co. has a 12 month low of $45.56 and a 12 month high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The company's 50 day moving average price is $64.98 and its 200 day moving average price is $77.66. The stock has a market capitalization of $3.21 billion, a price-to-earnings ratio of -30.01 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. On average, equities research analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on PRCT. Truist Financial restated a "buy" rating and issued a $90.00 price target (down from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Finally, Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.29.

Insider Buying and Selling

In related news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at $9,875,374.20. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock valued at $368,322 over the last three months. 17.40% of the stock is owned by company insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).